Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
Background With the rapid development of immune checkpoint inhibitors and neoantigen (NeoV)-based personalized tumor vaccines, tumor immunotherapy has shown promising therapeutic results. However, the limited efficacy of available tumor vaccines impedes the development of personalized tumor immunoth...
Saved in:
| Main Authors: | Pei Zhang, Ye Liu, Jie Tian, Jie Wang, Zhijie Wang, Hua Bai, Di Wang, Xiran He, Yang Du |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-02-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/2/e003564.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
by: Stephanie Dudzinski, et al.
Published: (2020-05-01) -
Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
by: Lucillia Bezu, et al.
Published: (2023-12-01) -
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment
by: Ze-Tao Zhan, et al.
Published: (2022-01-01) -
B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors
by: Jean-Yves Scoazec, et al.
Published: (2024-04-01) -
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
by: Hui Wang, et al.
Published: (2020-05-01)